Apogee Biotechnology
Focus: Apogee Biotechnology is a small-molecule oncology-focused biotech founded in 2001, currently operating as a private company based in Pennsylvania with a legacy portfolio of radiopharmaceutical diagnostics. The company maintains a modest clinical pipeline targeting hepatocellular carcinoma and related oncology indications.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
Funding Stage
PRIVATE
Open Jobs
0
About Apogee Biotechnology
AI assessmentNot HiringNo open roles listed right now. Follow Apogee Biotechnology to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
2/9 — Limited
Company HealthSolid
Pipeline
Early-stage
1 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Key Products
AMMONIA N-13
Declining
Post-LOE
An ANDA-approved radiopharmaceutical diagnostic with expired patent protection; revenue unlikely to be material or growing.
FLUDEOXYGLUCOSE F-18
Help build intelligence for Apogee Biotechnology
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.